Back to News
Market Impact: 0.15
Genmab Reaches Analyst Target Price
Source: Nasdaq
Analyst InsightsMarket Technicals & Flows
Genmab shares recently traded at $44.69, above the average analyst 12-month target price of $43.85. The article notes analysts may respond to a stock reaching its target by downgrading it on valuation; no specific analyst action is reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
GMAB0.10
More News
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge
- Stifel’s surprise gaming pick leads a sector bracing for a choppy earnings season
- Gold steadies above $4,000 as traders await Fed decision, PCE data
- What's behind the AI trade comeback — plus, our take on Intel's latest deal
- U.S. stock futures flat with Fed rate decision, megacap tech earnings on tap
- Margin debt growth slows sharply as stock market warning signs build